GleamWall
中文EN

HURA TuHURA Biosciences, Inc./NV

Pharmaceutical Preparations · Nasdaq · SEC CIK 1498382 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.2%
TTM EPS YoY-47.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-167.5%
ROA-96.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets47.7%
Debt / equity0.49x
Current ratio0.47x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-20.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue——$0$0$0$0$0$0
R&D expense$3.70M$6.62M$5.23M$6.06M$4.97M$4.93M$4.58M$3.98M
SG&A expense$1.96M$2.14M$2.30M-$1.56M$1.59M$1.86M$2.02M$1.72M
Interest expense$752,509$467,634$27,974$608,751$16,532$0—$522,835
Net income-$6.41M-$9.22M-$7.54M-$6.76M-$7.10M-$9.52M-$6.66M-$6.00M
EPS (basic)-0.10-0.14-0.13—-0.14-0.21-0.15—
EPS (diluted)-0.10-0.14-0.13—-0.14-0.21-0.15—
Weighted avg. shares (diluted)65.00M63.96M60.01M—50.67M44.56M43.40M—
Balance sheet
Cash & equivalents$1.89M$995,977$6.30M$3.62M$2.70M$8.51M$6.22M$12.66M
Current assets$3.68M$1.66M$6.98M$4.62M$3.50M$12.54M$14.33M$19.61M
PP&E, net$407,794$434,887$326,012$300,639$295,332$144,171$151,980$123,366
Goodwill$10.74M$10.74M$10.74M$10.74M$13.55M$13.55M——
Total assets$36.24M$31.75M$29.70M$27.35M$25.70M$34.62M$14.64M$19.97M
Current liabilities$7.76M$9.26M$6.07M$5.92M$8.83M$15.17M$4.78M$5.33M
Long-term debt$9.20M$3.60M——————
Total debt$9.20M$3.60M——————
Total liabilities$17.29M$13.25M$6.51M$6.42M$8.92M$15.17M$4.78M$5.37M
Shareholders' equity$18.95M$18.50M$23.19M$20.93M$16.78M$19.45M$9.86M$14.59M
Net debt$7.31M$2.60M——————
Shares outstanding65.76M63.68M63.58M59.34M51.25M49.91M43.68M12.17M
Cash flow statement
Operating cash flow-$5.01M-$8.63M-$4.41M-$5.56M-$11.09M-$6.25M-$4.74M-$2.60M
Capital expenditure$0$136,978$48,846$27,850$0$5,561$42,672$21,408
Free cash flow-$5.01M-$8.77M-$4.46M-$5.58M-$11.09M-$6.25M-$4.78M-$2.62M
Investing cash flow$0-$136,978-$48,846-$27,850$0-$156,464-$1.15M-$823,540
Financing cash flow$5.91M$3.47M$7.14M$6.51M$5.27M$8.70M-$547,878-$3.52M
Depreciation & amortization$27,000$28,000$23,472$22,544$21,000$14,000$14,058$17,635
Stock-based compensation$1.42M$2.14M$2.80M$2.15M$1.45M$1.41M$1.42M$1.08M

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.